SynthesisFrontiers in public health2026
Assessing the prevalence of anosmia and taste dysfunction in COVID-19 patients in Saudi Arabia: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Patients with coronavirus disease-2019 (COVID-19) frequently report olfactory and gustatory dysfunctions, including anosmia and ageusia. Multiple studies have assessed the prevalence of these symptoms in COVID-19 patients in Saudi Arabia. This systematic review and meta-analysis aimed to estimate the pooled prevalence of anosmia and taste dysfunction in confirmed COVID-19 patients in Saudi Arabia across inpatient, outpatient, and community settings, from March 2020 to March 2023. Methods: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. No review protocol was prospectively registered prior to this review. A comprehensive search was conducted across PubMed, ScienceDirect, CINAHL, MEDLINE, and Google Scholar (supplementary) from 1 March 2020 to 1 March 2023. Data were pooled using a random-effects model. The methodological quality of included studies was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools for prevalence studies. Results: Of 230 records identified across all databases, 156 remained after deduplication; 24 met the eligibility criteria, encompassing 26,068 COVID-19 patients (58.2% female). The pooled prevalence of anosmia was 44% (95% CI: 37-52%) and of taste dysfunction was 46% (95% CI: 39-54%). Subgroup analyses comparing validated versus non-validated assessment instruments revealed no statistically significant difference in prevalence estimates. Conclusion: Anosmia and taste loss are common manifestations of COVID-19 in Saudi Arabia. The findings should be interpreted with caution given the methodological heterogeneity of included studies, reliance on self-reported measures in the majority of studies, and the absence of a prospectively registered protocol. Future studies using objective validated instruments are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.